Claims
- 1. A suppository composition for rectal administration of a lincosamide antibacterial drug, comprising an antimicrobially effective amount of the lincosamide dispersed in a Hard Fat suppository base, wherein the lincosamide is in the form of solid particles.
- 2. The composition of claim 1, wherein the lincosamide is present in a form selected from the group consisting of a lincosamide salt and a lincosamide ester.
- 3. The composition of claim 1, wherein the lincosamide is present in the form of a lincosamide phosphate.
- 4. The composition of claim 1 wherein the lincosamide is present in said composition in an amount from about 0.1% by weight of the entire composition to about 60% by weight of the entire composition.
- 5. The composition of claim 1 wherein the lincosamide is selected from the group consisting of pirlimycin and lincomycin.
- 6. The composition of claim 1 wherein the lincosamide is clindamycin.
- 7. The composition of claim 6 wherein said composition contains 50 to 150 mg of the clindamycin is present in said composition in an amount from about 1.5% by weight of the entire composition to about 7.5% by weight of the entire composition.
- 8. The composition of claim 1 wherein said Hard Fat has a β polymorphic form which has a flow point in the range from 30° C. to 40° C.
- 9. The composition of claim 1 wherein said Hard Fat has a β polymorphic form which has a flow point of 37° C. or less.
- 10. The composition of claim 1 wherein the Hard Fat is a mixture of glyceride esters of vegetable C12-C18 saturated fatty acids containing at least about 50% triglyceride esters.
- 11. The composition of claim 1 wherein the particles of lincosamide have particle size of 10 μm or less.
- 12. The composition of claim 1 wherein the Hard Fat base is a Hard Fat NF suppository base having the following properties:
- 13. A method of rectally administering a lincosamide to a subject, comprising the steps of:
a) providing a suppository comprising an antimicrobially effective amount of the lincosamide, dispersed in a Hard Fat suppository base, wherein the lincosamide is in the form of particles, wherein the suppository is sufficiently small to pass through the anus of the subject; and b) inserting the rectal suppository into the rectum of the subject, through the anus.
- 14. The method of claim 13, wherein the subject is a mammal.
- 15. The method of claim 14, wherein the mammal is selected from the group consisting of a dog, a cat, a sheep, a cow, a steer, a goat, and a horse.
- 16. The method of claim 14, wherein the mammal is a human being.
- 17. The method of claim 13 wherein the lincosamide is selected from the group consisting of lincomycin and pirlimycin.
- 18. The method of claim 13 wherein the lincosamide is a clindamycin.
- 19. The method of claim 13, wherein the lincosamide is present in a form selected from the group consisting of a lincosamide salt and a lincosamide ester.
- 20. The method of claim 13, wherein the lincosamide is present in the form of a lincosamide phosphate.
- 21. The method of claim 13, wherein the lincosamide is present in the suppository in an amount from about 0.1% by weight to about 60% by weight of the entire composition.
- 22. The method of claim 13 wherein said Hard Fat has a β polymorphic form which has a flow point in the range from 30° C. to 40° C.
- 23. The method of claim 13 wherein said Hard Fat has a β polymorphic form which has a flow point of about 37° C. or less.
- 24. The method of claim 13 wherein the Hard Fat is a mixture of glyceride esters of vegetable C12-C18 saturated fatty acids containing at least about 50% triglyceride esters.
- 25. The method of claim 13 wherein the lincosamide has a particle size of 10 μm or less.
- 26. The method of claim 13 wherein the Hard Fat base is a Hard Fat NF suppository base having the following properties:
- 27. A method of treating a mammalian subject infected with at least one gram-positive, comprising the steps of:
a) providing a suppository comprising an antimicrobially effective amount of the lincosamide, dispersed in a Hard Fat suppository base, wherein the lincosamide is in the form of particles, wherein the suppository is sufficiently small to pass through the anus of the subject; b) inserting the rectal suppository into the rectum of the subject, through the anus; and c) repeating step (b) until the subject is cured of the infection.
- 28. The method of claim 27, wherein the mammal is a human being.
- 29. The method of claim 27 wherein the lincosamide is selected from the group consisting of lincomycin and pirlimycin.
- 30. The method of claim 27 wherein the lincosamide is a clindamycin.
- 31. The method of claim 27, wherein the lincosamide is present in a form selected from the group consisting of a lincosamide salt and a lincosamide ester.
- 32. The method of claim 27, wherein the lincosamide is present in the form of a lincosamide phosphate.
- 33. The method of claim 27 wherein the Hard Fat has a β polymorphic form which has a flow point in the range from 30° C. to 40° C.
- 34. The method of claim 27 wherein the Hard Fat is a mixture of glyceride esters of vegetable C12-C18 saturated fatty acids containing at least about 50% triglyceride esters.
- 35. The method of claim 27 wherein the lincosamide has a particle size of 10 μm or less.
- 36. The method of claim 27 wherein the Hard Fat base is a Hard Fat NF suppository base having the following properties:
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] The present patent application is a continuation-in-part of U.S. patent application Ser. No. 09/619,930, filed Jul. 20, 2000, that claims the benefit of U.S. Provisional Patent Application Serial No: 60/147,561, filed Aug. 6, 1999.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60147561 |
Aug 1999 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09619930 |
Jul 2000 |
US |
Child |
10072492 |
Feb 2002 |
US |